Ductal carcinoma in situ (DCIS) is a nonobligate precursor of invasive cancer, and its
detection, diagnosis, and management are controversial. DCIS incidence grew with the …

The cellular heterogeneity of breast cancers still represents a major therapeutic challenge.
The latest genomic studies have classified breast cancers in distinct clusters to inform the …

Ductal carcinoma in situ (DCIS) is a common precursor of invasive breast cancer. Our
understanding of its genomic progression to recurrent disease remains poor, partly due to …

The metastatic process is arduous. Cancer cells must escape the confines of the primary
tumor, make their way into and travel through the circulation, then survive and proliferate in …

Simple Summary Breast cancer is a major public health problem with a large impact on the
life of patients and their families. It is a highly curable disease when detected early, and an …

Breast cancer remains the most frequently diagnosed cancer in women worldwide. Tumors
that express hormone receptors account for 75% of all cases. Understanding alternative …

The drivers of ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) transition
are poorly understood. Here, we conducted an integrated genomic, transcriptomic, and …

Women with ductal carcinoma in situ (DCIS) have an increased risk of progression to
invasive breast cancer. Although not all women with DCIS will progress to invasion, all are …

Invasive ductal carcinoma (IDC) is the most common histological subtype of malignant
breast cancer (BC), and accounts for 70–80% of all invasive BCs. IDC demonstrates great …

Ductal carcinoma in situ (DCIS) represents pre-invasive breast carcinoma. In untreated
cases, 25–60% DCIS progress to invasive ductal carcinoma (IDC). The challenge lies in …